Dr Katie Ewer

Dr Katie Ewer
Address: The Jenner Institute, Old Road Campus Research Building
Roosevelt Drive, Oxford, OX3 7DQ
Tel: +44 (0)1865 617622




The wife scientific (@katier448) 

Principal areas of research: Malaria vaccines, pre-erythrocytic vaccines, Ebola vaccines, clinical trials, T cells, correlates of protection


As the senior immunologist for the Ebola and pre-erythrocytic malaria vaccine trials, I oversee the immunology on Phase I and II trials of vectored vaccines, both in the UK and in field trials in Africa. We use the chimpanzee adenovirus, ChAd63, as a priming vector and modified vaccinia virus (MVA) as a boosting vaccination and these viruses encode proteins from the organism that can elicit protective immune responses in our vaccinated volunteers.

The aim of my research is to define vaccine-induced immunological parameters that correlate with protection from malaria. I have access to samples from our volunteers that I can study using methods such as ELISPOT, flow cytometry and transcriptional profiling. By combining data from these different assays and analysing how these different measures relate to protection against malaria, I have been able to define the function and phenotype of T cells that are associated with protection in our human challenge model.

These findings can then be relayed back through the vaccine development process to improve the immunogenicity of our viral vectors for future trials and hopefully increase vaccine efficacy.

Key Publications

Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity". Ewer KJ, Sierra-Davidson K, Salman AM, Illingworth JJ, Draper SJ, Biswas S, Hill AV. Vaccine. 2015 Dec 22;33(52):7444-51. doi: 10.1016/j.vaccine.2015.09.094. 

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, S Hill AV, Bejon P; MVVC group. Sci Transl Med. 2015 May 6

ITV News coverage here: http://www.itv.com/news/meridian/update/2015-05-13/malaria-vaccine-breakthrough-could-save-thousands/

A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. Rampling T*, Ewer K*, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, Wilkie M, Venkatraman N, Poulton I, Lella N, Roberts R, Sierra-Davidson K, Krähling V, Berrie E, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Becker S, Graham BS, Koup RA, Levine MM, Moorthy V, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV. N Engl J Med. 2015 Jan 28.

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Faust SN, Hill AV. J Infect Dis. 2015 Apr 1;211(7):1076-86. doi: 10.1093/infdis/jiu579.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ. Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109.

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Ewer KJ*, O'Hara GA*, Duncan CJ*, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV. Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.